Abstract

Detection and management of early stage inflammatory bowel disease: an update for clinicians

Loy L1, Roda G1, Fiorino G1, Allocca M1, Furfaro F1, Argollo M1, Peyrin-Biroulet L2, Danese S1,3. Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):547-555. doi: 10.1080/17474124.2019.1605291. Epub 2019 Apr 22.

 
     

Author information

a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano, Milan , Italy.

b Department of Hepato-Gastroenterology and Inserm U954 , University Hospital of Nancy, Lorraine University , Vandoeuvre-lès-Nancy , France.

c Department of Biomedical Sciences , Humanitas Rozzano , Milan , Italy.

Abstract

Inflammatory bowel diseases, which include Crohn's disease and ulcerative colitis, are lifetime chronic and progressive disorders of poorly known etiology. Over the past few decades, new therapeutic approaches, including early and more aggressive intervention with immunomodulators and biological agents have offered the possibility of a favorable modification in the natural history of inflammatory bowel diseases. Area covered: Here, we review the literature about the effectiveness of early detection and intervention in adult inflammatory bowel diseases patients. Expert commentary: Detecting and managing early stages of inflammatory bowel diseases represents an effective strategy to avoid disease progression in selected patients. Primary care physicians may play a key role in attaining these outcomes by recognizing the signs and symptoms early and making timely referrals. Moreover, early therapeutic intervention with complete disease control may allow dose reduction or even treatment withdrawal in the maintenance phase, reducing side effects, costs, and also improving quality of life.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.